glp-1 bone density GLP-1s and Health: What the Evidence Says About Semaglutide, Bone Density, and Muscle Loss What You Need to Know

doi: 10.1002/hep.23569

Weight loss occurs in a dose-dependent way and exhibits a biphasic pattern: an initial quick phase induced by decreased calorie intake, followed by a slower phase indicative of metabolic tolerance and enduring behavioural modifications

Tirzepatide acts as a dual agonist of the GLP-1 and GIP receptors, enhancing insulin secretion, suppressing glucagon release, and promoting feelings of fullness

Drinking small amounts and avoiding alcohol during dose increases can help reduce side effects

(I am a big advocate of spacing out doses for people who have reached their goal weight, OR who are taking GLP-1s primarily for a possible metabolic/anti-inflammatory benefit, and who want to keep their weight neutral.) But maintenance dosing after achieving a clinical response is a completely different concept from starting at a sub-therapeutic dose and hoping it works